Moxifloxacin

C. diff Risk

High

Oral Bioavailability

Excellent

Spectrum Of Activity

Dosing

400 mg IV/PO daily

No adjustment required

General Information

Monitor QTc in patients with increased risk

  • QTc prolongation

  • Dysglycemia

  • Rash

  • Tendinopathy and rupture

  • GI upset

  • Increased Liver Function Tests

  • Weakness exacerbation in myasthenia gravis

  • CNS toxicity including confusion, psychosis

QTc prolongation - Increased risk with other agents that prolong QTc

Divalent cations including Ca, Mg - Decreased absorption

Warfarin - Increased INR

Rifampin - Decrease moxifloxacin levels

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 12 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Poor

Pneumonia including CAP, HAP, aspiration

Some intra-abdominal infections

CNS infections